Skip to main content
Premium Trial:

Request an Annual Quote

UK Agency Recommends Roche, Qiagen Tests, Sanger Sequencing for Some NSCLC Patients

NEW YORK (GenomeWeb News) – The UK agency advising the National Health Service which tests it should make available to the public on Tuesday recommended five tests and testing technologies for certain patients with non-small cell lung cancer.

In a final guidance, the National Institute for Health and Care Excellence, or NICE, recommended the tests for detecting epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutations in tumors of adults with previously untreated, locally advanced, or metastatic NSCLC to inform first-line decisions.

The tests recommended are Qiagen's Therascreen EGFR RGQ PCR Kit; Roche's Cobas EGFR Mutation Test; Sanger sequencing of samples with more than 30 percent tumor cells and Therascreen EGFR RGQ PCR Kit for sample with lower tumor cell contents; Sanger sequencing of samples with more than 30 percent tumor cells and Cobas EGFR Mutation Test for samples with lower tumor cell contents; and Sanger sequencing followed by fragment length analysis and PCR of negative samples.

NICE declined to recommend five other technologies because of "insufficient evidence," however. They include next-generation sequencing; Qiagen's Therascreen EGFR Pyro Kit; pyrosequencing combined with fragment length analysis; single-strand conformation polymorphism analysis; and high resolution melt analysis.

Qiagen's Therascreen EGFR RGQ PCR Kit is a CE-marked real-time PCR assay that detects 29 mutations in exons 18 and 21 of the EGFR-TK gene. In July, the US Food and Drug Administration approved the assay as a companion diagnostic for Boehringer Ingelheim's Gilotrif (afatinib) for treating NSCLC patients with tumors with certain EGFR mutations.

Roche's Cobas EGFR Mutation Test also is a CE-marked real-time PCR test and detects 41 mutations in exons 18 and 21 in the EGFR-TK gene. In May, FDA approved the assay as a companion diagnostic for Tarceva (erlotinib), jointly marketed in the US by Roche's Genentech business and Astellas Pharma.

In a statement, Roche said that while there are many different types of tests for EGFR-TK mutations being used in NHS labs in England, NICE aimed at identifying the "most clinically and cost-effective tests that should be used to inform first-line treatment decisions."

The prices charged by NHS labs for the five recommended tests ranged from £130 ($202) for Sanger sequencing for Roche's Mutation Test for samples with insufficient tumor cells, to £154.58 ($239.73) for Qiagen's test, NICE said.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.